3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
9
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Adenocarcinoma
2
Salivary Gland Neoplasms
1
Refractory or Relapsed Solid Tumors
1
Prostatic Neoplasms, Castration-Resistant
1
Metastatic Castration-resistant Prostate Neoplasms
1
Bulbo-Spinal Atrophy, X-Linked
1
Biochemically Recurrent Prostate Cancer
1
Interventions
relugolix
1
enzalutamide
1
Specimen Handling
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Radiation
1
Magnetic Resonance Spectroscopy
1
Biopsy
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Prostate Adenocarcinoma
×
darolutamide
×
30 days
×
Clear all
No trials found.